These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
152 related articles for article (PubMed ID: 33416848)
1. SARS-CoV-2 3D database: understanding the coronavirus proteome and evaluating possible drug targets. Alsulami AF; Thomas SE; Jamasb AR; Beaudoin CA; Moghul I; Bannerman B; Copoiu L; Vedithi SC; Torres P; Blundell TL Brief Bioinform; 2021 Mar; 22(2):769-780. PubMed ID: 33416848 [TBL] [Abstract][Full Text] [Related]
2. Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses. Artese A; Svicher V; Costa G; Salpini R; Di Maio VC; Alkhatib M; Ambrosio FA; Santoro MM; Assaraf YG; Alcaro S; Ceccherini-Silberstein F Drug Resist Updat; 2020 Dec; 53():100721. PubMed ID: 33132205 [TBL] [Abstract][Full Text] [Related]
3. Ligand-based approach for predicting drug targets and for virtual screening against COVID-19. Yang Y; Zhu Z; Wang X; Zhang X; Mu K; Shi Y; Peng C; Xu Z; Zhu W Brief Bioinform; 2021 Mar; 22(2):1053-1064. PubMed ID: 33461215 [TBL] [Abstract][Full Text] [Related]
4. Functional and druggability analysis of the SARS-CoV-2 proteome. Cavasotto CN; Lamas MS; Maggini J Eur J Pharmacol; 2021 Jan; 890():173705. PubMed ID: 33137330 [TBL] [Abstract][Full Text] [Related]
5. Multilevel proteomics reveals host perturbations by SARS-CoV-2 and SARS-CoV. Stukalov A; Girault V; Grass V; Karayel O; Bergant V; Urban C; Haas DA; Huang Y; Oubraham L; Wang A; Hamad MS; Piras A; Hansen FM; Tanzer MC; Paron I; Zinzula L; Engleitner T; Reinecke M; Lavacca TM; Ehmann R; Wölfel R; Jores J; Kuster B; Protzer U; Rad R; Ziebuhr J; Thiel V; Scaturro P; Mann M; Pichlmair A Nature; 2021 Jun; 594(7862):246-252. PubMed ID: 33845483 [TBL] [Abstract][Full Text] [Related]
6. Human cell receptors: potential drug targets to combat COVID-19. Raghav PK; Kalyanaraman K; Kumar D Amino Acids; 2021 Jun; 53(6):813-842. PubMed ID: 33950300 [TBL] [Abstract][Full Text] [Related]
7. SARS-CoV-2 protein drug targets landscape: a potential pharmacological insight view for the new drug development. Chakraborty C; Bhattacharya M; Mallick B; Sharma AR; Lee SS; Agoramoorthy G Expert Rev Clin Pharmacol; 2021 Feb; 14(2):225-238. PubMed ID: 33423554 [No Abstract] [Full Text] [Related]
9. Current approaches for target-specific drug discovery using natural compounds against SARS-CoV-2 infection. Khare P; Sahu U; Pandey SC; Samant M Virus Res; 2020 Dec; 290():198169. PubMed ID: 32979476 [TBL] [Abstract][Full Text] [Related]
10. Mapping major SARS-CoV-2 drug targets and assessment of druggability using computational fragment screening: Identification of an allosteric small-molecule binding site on the Nsp13 helicase. Freidel MR; Armen RS PLoS One; 2021; 16(2):e0246181. PubMed ID: 33596235 [TBL] [Abstract][Full Text] [Related]
11. Screening, simulation, and optimization design of small molecule inhibitors of the SARS-CoV-2 spike glycoprotein. Sun C; Zhang J; Wei J; Zheng X; Zhao X; Fang Z; Xu D; Yuan H; Liu Y PLoS One; 2021; 16(1):e0245975. PubMed ID: 33493227 [TBL] [Abstract][Full Text] [Related]
12. Assessment of antiviral potencies of cannabinoids against SARS-CoV-2 using computational and in vitro approaches. Raj V; Park JG; Cho KH; Choi P; Kim T; Ham J; Lee J Int J Biol Macromol; 2021 Jan; 168():474-485. PubMed ID: 33290767 [TBL] [Abstract][Full Text] [Related]
13. Knowing and combating the enemy: a brief review on SARS-CoV-2 and computational approaches applied to the discovery of drug candidates. Serafim MSM; Gertrudes JC; Costa DMA; Oliveira PR; Maltarollo VG; Honorio KM Biosci Rep; 2021 Mar; 41(3):. PubMed ID: 33624754 [TBL] [Abstract][Full Text] [Related]
14. Pharmacoinformatics approach based identification of potential Nsp15 endoribonuclease modulators for SARS-CoV-2 inhibition. Savale RU; Bhowmick S; Osman SM; Alasmary FA; Almutairi TM; Abdullah DS; Patil PC; Islam MA Arch Biochem Biophys; 2021 Mar; 700():108771. PubMed ID: 33485847 [TBL] [Abstract][Full Text] [Related]
15. Bioactive Terpenes and Their Derivatives as Potential SARS-CoV-2 Proteases Inhibitors from Molecular Modeling Studies. Diniz LRL; Perez-Castillo Y; Elshabrawy HA; Filho CDSMB; de Sousa DP Biomolecules; 2021 Jan; 11(1):. PubMed ID: 33430299 [TBL] [Abstract][Full Text] [Related]
16. Modeling of SARS-CoV-2 Virus Proteins: Implications on Its Proteome. Sarkar M; Saha S Methods Mol Biol; 2023; 2627():265-299. PubMed ID: 36959453 [TBL] [Abstract][Full Text] [Related]
17. Nanomedicine for the SARS-CoV-2: State-of-the-Art and Future Prospects. Varahachalam SP; Lahooti B; Chamaneh M; Bagchi S; Chhibber T; Morris K; Bolanos JF; Kim NY; Kaushik A Int J Nanomedicine; 2021; 16():539-560. PubMed ID: 33519200 [TBL] [Abstract][Full Text] [Related]
18. Potential inhibitors for the novel coronavirus (SARS-CoV-2). Han Y; Wang Z; Ren J; Wei Z; Li J Brief Bioinform; 2021 Mar; 22(2):1225-1231. PubMed ID: 32942296 [TBL] [Abstract][Full Text] [Related]
19. Peptide Derivatives of the Zonulin Inhibitor Larazotide (AT1001) as Potential Anti SARS-CoV-2: Molecular Modelling, Synthesis and Bioactivity Evaluation. Di Micco S; Musella S; Sala M; Scala MC; Andrei G; Snoeck R; Bifulco G; Campiglia P; Fasano A Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502335 [TBL] [Abstract][Full Text] [Related]
20. DockCoV2: a drug database against SARS-CoV-2. Chen TF; Chang YC; Hsiao Y; Lee KH; Hsiao YC; Lin YH; Tu YE; Huang HC; Chen CY; Juan HF Nucleic Acids Res; 2021 Jan; 49(D1):D1152-D1159. PubMed ID: 33035337 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]